Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
September 06, 2023 16:05 ET
|
Corvus Pharmaceuticals, Inc.
Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024 Company to host conference call and webcast tomorrow at 8:30 a.m. ET / 5:30 a.m. PT BURLINGAME, Calif.,...
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
August 08, 2023 16:01 ET
|
Corvus Pharmaceuticals, Inc.
Interim Phase 1/1b clinical results with soquelitinib and published clinical studies on mechanism of action continue to support potential of ITK inhibition as novel immunotherapy for hematologic and...
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
August 01, 2023 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference...
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
July 06, 2023 12:59 ET
|
Corvus Pharmaceuticals, Inc.
Data highlights the differentiated mechanism of action of soquelitinib to enhance anti-tumor immune response to hematologic and solid tumorsSoquelitinib shown to increase infiltration of cancer...
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
June 29, 2023 07:00 ET
|
Corvus Pharmaceuticals, Inc.
Preclinical data highlights ciforadenant’s mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues in Phase 1b/2 clinical trial evaluating ciforadenant as a potential...
Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma
June 15, 2023 07:00 ET
|
Corvus Pharmaceuticals, Inc.
Data supported CPI-818’s novel immunotherapy mechanism of action and its potential to provide a platform approach to a broad range of solid and hematological cancers Laboratory and clinical data...
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 31, 2023 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president...
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
May 17, 2023 09:00 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
May 08, 2023 16:01 ET
|
Corvus Pharmaceuticals, Inc.
Updated interim results from CPI-818 Phase 1/1b clinical trial continues to support potential of ITK inhibition and the ALC biomarker in T cell lymphoma Conference Call Today at 4:30 p.m. ET / 1:30...
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
April 20, 2023 09:00 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a...